Adenosine myocardial protection: Preliminary results of a phase II clinical trial

Annals of Surgery

Volumn 229, Issue 5, 1999, Pages 643-650

  Mentzer Jr , Robert M ^a,h   Birjiniuk, Vladimir ^b   Khuri, Shukri ^b   Lowe, James E ^c   Rahko, Peter S ^d   Weisel, Richard D ^e   Wellons, Harry A ^f   Barker, Matthew L ^g   Lasley, Robert D ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^e UNIVERSITY HEALTH NETWORK   (Canada)

^f ST JOHN'S HOSPITAL   (United States)

^g UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^h UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ADRENALIN; AMRINONE; DOBUTAMINE; DOPAMINE; INOTROPIC AGENT; ISOPRENALINE; MILRINONE; NORADRENALIN; PLACEBO;

AORTA BALLOON; AORTA CLAMPING; CARDIOPLEGIA; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; HEART INFARCTION; HEART PROTECTION; HEART VENTRICLE PERFORMANCE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURGICAL MORTALITY;

ADENOSINE; CARDIOVASCULAR AGENTS; CORONARY ARTERY BYPASS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE;

EID: 0343184098     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000658-199905000-00006     Document Type: Conference Paper

References (26)

1. Lasley RD. Adenosine, cardioprotection and potential mechanisms. In Mentzer RM, Kitakaze M, Downey JM, Hori M, eds. Adenosine, cardioprotection and its clinical application. Norwell, MA: Kluwer Academic Publishers; 1997:93-102.
2. 1 receptor system. Cardiovasc Res 1993; 27:28-35.
3. Mentzer RM Jr, Rahko PS, Molina-Viamonte V, et al. Safety, tolerance, and efficacy of adenosine as an additive to blood cardioplegia in humans during coronary artery bypass surgery. Am J Cardiol 1997; 79:38-43.
4. Milliken GA, Johnson DE. Analysis of repeated measures designs for which the usual assumptions hold. In Mason R, Scheier B, eds. Analysis of messy data volume I: designed experiments. Belmont, CA: Lifetime Learning Publications; 1984:322-350.
5. Bolli R. Myocardial "stunning" in man. Circulation 1992; 86:1671-91.
6. Leung JM. Clinical evidence of myocardial stunning in patients undergoing CABG surgery. J Card Surg 1993; 8:220-223.
7. Hudspeth DA, Nakanishi K, Vinten-Johansen J, et al. Adenosine in blood cardioplegia prevents postischemic dysfunction in ischemically injured hearts. Ann Thorac Surg 1994; 58:1637-1644.
8. Randhawa MPS Jr, Lasley RD, Mentzer RM Jr. Salutary effects of exogenous adenosine on canine myocardial stunning in vivo. J Thorac Cardiovasc Surg 1995; 110:63-74.
9. Lasley RD, Konyn PJ, Hegge JO, Mentzer RM Jr. The effects of ischemic and adenosine preconditioning on interstitial fluid adenosine and myocardial infarct size. Am J Physiol 1995; 269:H1460-H1466.
10. Auchampach JA, Rizvi A, Qiu Y, et al. Selective activation of A3 adenosine receptors with N6-(3-iodobenzyl)adenosine-5′-N-methyl-uronamide protects against myocardial stunning and infarction without hemodynamic changes in conscious rabbits. Circ Res 1997; 80:800-809.
11. 2 receptor activation attenuates reperfusion injury by inhibiting neutrophil accumulation, superoxide generation and coronary endothelial adherence. J Pharmacol Exp Ther 1997; 280:301-309.
12. Lasley RD, Zhou Z, Hegge JO, et al. Adenosine attenuates in vivo myocardial stunning with minimal effects on cardiac energetics. Basic Res Cardiol 1998; 93:303-312.
13. Zhou Z, Lasley RD, Hegge JO, et al. Myocardial stunning: a therapeutic conundrum. J Thorac Cardiovasc Surg 1995; 110:1391-1401.
14. 1 receptor-mediated cardioprotection in stunned canine myocardium. Circulation 1993; 88:235-244.
15. Cronstein BN, Kramer SB, Weissmann G, et al. Adenosine: a physiological modulator of superoxide anion generation by human neutrophils. J Exper Med 1983; 158:1160-1177.
16. Agarwal KC. Modulation of platelet function by plasma adenosine levels. In Imai S, Nakazawa M, eds. Role of adenosine and adenine nucleotides in the biological system. Amsterdam: Elsevier Science Publishers BV; 1991:457-468.
17. Wilbur SL, Marchlinski FE. Adenosine as an antiarrhythmic agent. Am J Cardiol 1997; 79:30-37.
18. Iskandrian AE, Heo J. Myocardial perfusion imaging during adenosine-induced coronary hyperemia. Am J Cardiol 1997; 79:20-24.
19. Owall A, Ehrenberg J, Brodin LA, et al. Effects of low-dose adenosine on myocardial performance after coronary artery bypass surgery. Acta Anaesthesiol Scand 1993; 37:140-148.
20. Fullerton DA, Jones SD, Grover FL, McIntyre RC Jr. Adenosine effectively controls pulmonary hypertension after cardiac operations. Ann Thorac Surg 1996; 61:118-123.
21. Leesar MA, Stoddard M, Ahmed M, et al. Preconditioning of human myocardium with adenosine during coronary angioplasty. Circulation 1997; 95:2500-2507.
22. Garratt KN, Holmes DR Jr, Molina-Viamonte V, et al. Intravenous adenosine and lidocaine in patients with acute myocardial infarction. Am Heart J 1998; 136:196-204.
23. Marzilli M, Marraccini P, Gliozheni E, et al. Intracoronary adenosine as an adjunct to combined use of primary angioplasty in acute myocardial infarction: beneficial effects on angiographically assessed noreflow [abstract]. J Am Coll Cardiol 1996; 28(suppl):406A.
24. Lee HT, Lafaro RJ, Reed GE. Pretreatment of human myocardium with adenosine during open heart surgery. J Cardiac Surg 1995; 10:665-676.
25. Fremes SE, Levy SL, Christakis GT, et al. Phase 1 human trial of adenosine-potassium cardioplegia. Circulation 1996; 94:370-375.
26. Cohen G, Feder-Elituv R, Iazetta J, et al. Phase 2 studies of adenosine cardioplegia. Circulation 1998; 98:II225-II233.